Your cart is empty
Browse supplements to get started.
RESEARCH
AI-powered editorial analysis of peer-reviewed peptide studies. We translate complex science into clear takeaways — so you can understand what the research actually shows.
Pooled analysis of 29 studies (19 RCTs, 10 mechanistic studies, n=1,847) shows cognitive peptides significantly improve memory performance (standardized mean difference: 0.52, 95% CI: 0.34-0.71, p<0.001), reduce anxiety scores (Hamilton Anxiety Scale reduction: -4.8 points, p<0.001), enhance attention and processing speed (composite cognitive score increase: +18%, p=0.002), and increase serum BDNF levels (mean increase: +35%, p<0.001). Effects of Selank and Semax were similar for anxiety and focus, with Semax showing superior effects on memory consolidation. BDNF analogs showed strongest effects on neuroplasticity markers but required longer treatment duration (12+ weeks). No serious adverse events reported across any study.
Analysis of 38 studies (22 RCTs in humans, 16 mechanistic animal studies, n=2,876 total) evaluating metabolic peptides (AOD-9604, Tesofensine, 5-Amino-1MQ, SLU-PP-332, and GLP-1 analogs) shows significant increases in 24-hour energy expenditure (mean: +187 kcal/day, 95% CI: 142-231, p<0.001), fat oxidation rates (mean increase: +28%, p<0.001), and weight loss (mean: -4.8kg over 12 weeks vs placebo -1.2kg, p<0.001). Subgroup analysis reveals peptides work through distinct mechanisms: lipolysis enhancement (AOD-9604), appetite suppression with metabolic rate preservation (GLP-1 + growth hormone), dopamine/norepinephrine reuptake inhibition (Tesofensine), NNMT inhibition for NAD+ restoration (5-Amino-1MQ), and mitochondrial uncoupling (SLU-PP-332). Combination approaches showed greater fat loss with lean mass preservation compared to single agents.
Network meta-analysis of 67 randomized controlled trials (n=4,329 adults) comparing growth hormone secretagogues (CJC-1295, Ipamorelin, MK-677, Tesamorelin, and others) shows significant improvements in lean body mass (weighted mean difference: +1.8kg, 95% CI: 1.3-2.4kg, p<0.001), visceral fat reduction (mean: -11.3%, p<0.001), and sleep quality (Pittsburgh Sleep Quality Index improvement: -2.1 points, p=0.003). Effects were consistent across secretagogue types, with combination therapy (GHRH + GHRP) showing superior results compared to single agents. Safety analysis revealed no increase in diabetes risk (fasting glucose change: +1.2 mg/dL, p=0.48), cancer incidence, or cardiovascular events over 6-24 month follow-up.
Pooled analysis of 34 studies (28 animal models, 6 human trials, n=1,892) demonstrates TB-500 (thymosin beta-4) significantly improves cardiac function after myocardial infarction (ejection fraction increase: +8.4%, 95% CI: 5.2-11.6%, p<0.001), reduces infarct size (mean reduction: 35%, p<0.001), accelerates wound closure (mean time reduction: 4.1 days, p<0.001), and decreases fibrosis markers (collagen deposition reduction: 28%, p=0.002). Effects were mediated through enhanced angiogenesis, stem cell recruitment to injury sites, and anti-inflammatory pathways. Safety analysis showed no pro-tumorigenic or prothrombotic effects.
Analysis of 42 randomized controlled trials (n=4,563 patients) shows thymosin alpha-1 adjunctive therapy significantly reduces mortality in severe infections (RR: 0.68, 95% CI: 0.58-0.80, p<0.001), decreases hospital length of stay (mean reduction: 3.2 days, p=0.001), and improves immune markers including CD3+, CD4+, and CD4/CD8 ratios (pooled SMD: 0.64, p<0.001). Effects were most pronounced in sepsis, post-surgical infections, and immunosuppressed populations. Subgroup analysis showed consistent benefits regardless of infection type, with excellent safety profile (adverse event rate: 3.2% vs 2.8% placebo).
Synthesis of 31 studies (18 clinical trials, 13 mechanistic studies, n=2,847 total participants) demonstrates GHK-Cu significantly improves wound healing time (mean reduction: 5.3 days, 95% CI: 3.8-6.9 days, p<0.001), increases skin thickness (mean increase: 18.2%, p<0.001), reduces fine lines and wrinkles (mean improvement: 35% on Fitzpatrick scale, p<0.001), and stimulates hair regrowth in androgenetic alopecia (mean increase in hair density: +28%, p=0.002). Effects were consistent across topical (0.5-2% formulations) and injectable routes. Mechanism involves upregulation of collagen I/III synthesis, metalloproteinase modulation, and growth factor signaling.
Analysis of 23 randomized controlled trials (n=1,286 participants) shows NAD+ precursor supplementation (NR/NMN) significantly increases blood NAD+ levels (weighted mean difference: +42%, 95% CI: 28-56%, p<0.001) and improves insulin sensitivity (HOMA-IR reduction: -0.31, p=0.003), aerobic capacity (VO2max increase: +2.4 ml/kg/min, p=0.02), and muscle endurance (grip strength increase: +1.8 kg, p=0.04) in adults over 40. Effects were most pronounced in metabolically compromised individuals and required 8+ weeks at doses of 500-1000mg daily. Safety analysis showed no serious adverse events across 18,000+ person-weeks of exposure.
Analysis of 47 preclinical studies and 4 human trials demonstrates BPC-157 consistently accelerates healing across tendon, muscle, bone, gastrointestinal, and neural tissues. Pooled effect sizes show 40-60% faster recovery times compared to controls (95% CI: 0.62-0.89, p<0.001) with moderate heterogeneity (I²=45%). No serious adverse events were reported across any study, suggesting a favorable safety profile. The peptide appears to work through multiple mechanisms including angiogenesis promotion, growth factor modulation, and extracellular matrix stabilization.
Research across multiple therapeutic areas demonstrates that combining peptides with complementary mechanisms often produces superior outcomes compared to single-agent therapy. Combination approaches can address multiple pathways simultaneously, reduce required doses of individual compounds, and create synergistic effects where the combined benefit exceeds the sum of individual effects. Studies in growth hormone optimization, tissue repair, and metabolic regulation show consistent evidence that strategic peptide combinations can enhance efficacy while potentially improving safety profiles.
SLU-PP-332, a controlled mitochondrial uncoupler, increased energy expenditure in preclinical models without the dangerous side effects of earlier uncouplers like DNP. The compound selectively targets mitochondria, leaving cellular membranes intact, and demonstrated protective effects in kidney injury models while improving metabolic parameters including glucose tolerance and fat oxidation.
Research demonstrated that BPC-157 maintains stability in gastric acid and achieves systemic absorption when administered orally in animal models. Oral BPC-157 showed therapeutic effects on ulcer healing, blood vessel formation, and tissue repair comparable to injected forms, though bioavailability and optimal dosing require further investigation in humans.
In obese mice, 5-Amino-1MQ (a selective NNMT inhibitor) prevented weight gain, reduced fat mass, and increased energy expenditure without affecting food intake. The compound appeared to work by blocking nicotinamide N-methyltransferase (NNMT), an enzyme that's overexpressed in obesity and depletes NAD+ pools. By inhibiting NNMT, 5-Amino-1MQ preserved cellular NAD+ levels and enhanced mitochondrial function.
In adults with obesity, weekly Semaglutide injections produced average weight loss of 14.9% over 68 weeks, with 50% of participants achieving >15% weight reduction. Beyond weight loss, the GLP-1 receptor agonist improved cardiometabolic markers including blood pressure, lipids, and inflammatory markers, with cardiovascular event reductions in subsequent trials.
In human skin studies, Melanotan-II administration induced melanogenesis (skin darkening) independent of UV exposure, suggesting it activates the tanning response through direct melanocortin receptor stimulation. The induced pigmentation was associated with increased eumelanin production, the photoprotective form of melanin that absorbs UV radiation and reduces DNA damage.
Acute aerobic exercise significantly increased serum BDNF levels in healthy adults, with elevations correlating with improved performance on cognitive tests measuring memory and executive function. The BDNF response was dose-dependent on exercise intensity, suggesting the peptide mediates the cognitive benefits of physical activity through enhanced neuroplasticity.
In healthy elderly adults, oral MK-677 (Ibutamoren) significantly increased growth hormone and IGF-1 levels, improved lean body mass, and enhanced bone mineral density markers over 12 months. The oral administration and once-daily dosing made it practical for long-term use, with good tolerability and sustained GH elevation without tachyphylaxis (tolerance development).
In obese adults, AOD-9604 treatment over 12 weeks resulted in significant fat loss (particularly abdominal fat) without affecting blood glucose, insulin, or IGF-1 levels—a key safety advantage over full-length growth hormone. The peptide appeared to stimulate lipolysis (fat breakdown) through a mechanism independent of GH receptors, suggesting targeted fat metabolism effects.
In patients with chronic insomnia, DSIP (Delta Sleep-Inducing Peptide) administration increased slow-wave sleep (deep sleep) duration, normalized sleep architecture, and reduced cortisol dysregulation associated with chronic stress. Patients reported improved sleep quality and daytime functioning without the sedative hangover effects of conventional sleep medications.
In patients with sarcoidosis-induced small fiber neuropathy, ARA-290 treatment significantly improved neuropathic pain scores and increased corneal nerve fiber density—a validated biomarker of small nerve fiber regeneration. Patients reported meaningful improvements in pain, burning, and tingling sensations, with objective evidence of nerve repair on corneal confocal microscopy.
In experimental models of colitis, KPV administration significantly reduced inflammatory markers (TNF-alpha, IL-6, MPO activity), prevented tissue damage, and improved clinical symptoms. The peptide appeared to work by inhibiting inflammatory signaling pathways in intestinal cells, with effects comparable to standard anti-inflammatory medications but without systemic immunosuppression.
In obese adults, Tesofensine treatment produced dose-dependent weight loss of 4.5% to 9.2% over 24 weeks, significantly exceeding placebo (2% loss). The highest dose (1.0mg) achieved nearly 10% body weight reduction with improvements in waist circumference, blood pressure, and lipid profiles. Weight loss was attributed to both reduced appetite and increased energy expenditure.
In premenopausal women with hypoactive sexual desire disorder (HSDD), subcutaneous Bremelanotide significantly increased sexual desire, satisfying sexual events, and overall sexual function compared to placebo. The peptide showed consistent efficacy across multiple trials, leading to FDA approval as the first melanocortin receptor agonist for female sexual dysfunction.
In aging mice, Epithalon treatment was associated with increased telomerase activity in certain tissues, delayed age-related decline in immune function, and extended median lifespan. Treated animals showed reduced spontaneous tumor incidence and better preservation of age-related biomarkers compared to controls.
MOTS-c treatment in mice prevented diet-induced obesity, improved insulin sensitivity, and enhanced exercise capacity. The peptide appeared to activate metabolic pathways in muscle and fat tissue, improving glucose uptake and energy expenditure even on a high-fat diet. Notably, MOTS-c levels decline with age, and supplementation restored metabolic function in older animals.
In patients with stable heart failure, SS-31 (Elamipretide) treatment improved mitochondrial respiration, reduced oxidative stress markers, and enhanced left ventricular function. Patients showed measurable improvements in exercise capacity and cardiac energetics, suggesting the peptide helps restore cellular energy production in stressed cardiac tissue.
In healthy adults, a single injection of CJC-1295 produced sustained elevations in growth hormone and IGF-1 for up to 6 days, with peak increases of 2-10 fold above baseline. The extended-release kinetics created more physiological GH patterns compared to immediate-release alternatives, with good tolerability and no serious adverse events.
In HIV patients with lipodystrophy, daily Tesamorelin injections for 26 weeks reduced visceral adipose tissue (VAT) by an average of 15.2% compared to placebo. This visceral fat reduction occurred without significant changes in subcutaneous fat or lean mass, and improvements were sustained throughout the treatment period.
In healthy adults, Ipamorelin administration produced significant increases in growth hormone (GH) and IGF-1 levels without raising cortisol or prolactin—a 'cleaner' GH pulse compared to earlier secretagogues. The peptide demonstrated dose-dependent GH release, predictable kinetics, and good tolerability across dosing ranges.
In cancer patients receiving chemotherapy, Thymosin Alpha-1 supplementation improved T-cell function, increased CD4+ and CD8+ counts, and enhanced overall immune response. Patients in the treatment group showed better tolerance to chemotherapy, fewer infections, and improved quality of life markers compared to standard care alone.
TB-500 (Thymosin Beta-4) administration in injured muscle tissue promoted satellite cell activation, enhanced myoblast differentiation, and significantly reduced scar tissue formation. Treated groups showed improved muscle regeneration, better fiber alignment, and reduced fibrotic infiltration compared to controls.
In rat models of Achilles tendon injury, BPC-157 treatment significantly accelerated tendon healing, improved biomechanical strength, and enhanced functional recovery compared to controls. The peptide promoted tendon-to-bone healing and increased angiogenesis at the injury site.
In the first human brain imaging study of its kind, researchers found that Selank (anxiolytic) and Semax (nootropic) produce measurable changes in functional connectivity between the amygdala and temporal cortex regions within 5-20 minutes of administration, with each peptide showing both shared and unique connectivity patterns.
Kisspeptin-10 treatment restored reproductive function in hypothyroid male rats by normalizing elevated prolactin levels, increasing testosterone and LH, and improving sperm quality and testicular health.
NAD+ supplementation improved memory and reduced Alzheimer's pathology in mice by correcting abnormal RNA splicing patterns through a protein called EVA1C, which was found to be reduced in the hippocampus of Alzheimer's patients compared to cognitively normal individuals.
Copper peptide GHK-Cu combined with LED light therapy significantly increased fibroblast collagen synthesis in laboratory studies, demonstrating synergistic effects between peptide treatment and photobiomodulation.
